193 related articles for article (PubMed ID: 11213849)
1. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Jellison TK; Mckinnon PS; Rybak MJ
Pharmacotherapy; 2001 Feb; 21(2):142-8. PubMed ID: 11213849
[TBL] [Abstract][Full Text] [Related]
2. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
Wood GC; Hanes SD; Croce MA; Fabian TC; Boucher BA
Clin Infect Dis; 2002 Jun; 34(11):1425-30. PubMed ID: 12015687
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic therapy for foot infections in diabetics.
Hu XH; Markson LE; Abbott TA; Dasbach EJ; Berger ML
Clin Infect Dis; 1997 Dec; 25(6):1488-90. PubMed ID: 9431413
[No Abstract] [Full Text] [Related]
8. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.
Corbella X; Ariza J; Ardanuy C; Vuelta M; Tubau F; Sora M; Pujol M; Gudiol F
J Antimicrob Chemother; 1998 Dec; 42(6):793-802. PubMed ID: 10052904
[TBL] [Abstract][Full Text] [Related]
10. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis.
Cawley MJ; Suh C; Lee S; Ackerman BH
Pharmacotherapy; 2002 Apr; 22(4):527-32. PubMed ID: 11939689
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
12. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.
Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Higashiyama Y; Miyazaki Y; Hirakata Y; Tomono K; Mizuta Y; Tsukamoto K; Kohno S
Intern Med; 2006; 45(17):995-9. PubMed ID: 17015999
[TBL] [Abstract][Full Text] [Related]
13. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.
Urban C; Go E; Mariano N; Berger BJ; Avraham I; Rubin D; Rahal JJ
J Infect Dis; 1993 Feb; 167(2):448-51. PubMed ID: 8421178
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam.
Jiménez-Mejías ME; Pachón J; Becerril B; Palomino-Nicás J; Rodríguez-Cobacho A; Revuelta M
Clin Infect Dis; 1997 May; 24(5):932-5. PubMed ID: 9142795
[TBL] [Abstract][Full Text] [Related]
15. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.
Levin AS; Levy CE; Manrique AE; Medeiros EA; Costa SF
Int J Antimicrob Agents; 2003 Jan; 21(1):58-62. PubMed ID: 12507838
[TBL] [Abstract][Full Text] [Related]
16. Extensively-drug resistant
Gkentzi D; Tsintoni A; Christopoulou I; Mamalis I; Paliogianni F; Assimakopoulos SF; Marangos M; Dimitriou G
J Chemother; 2020 Apr; 32(2):103-106. PubMed ID: 31992156
[No Abstract] [Full Text] [Related]
17. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
Ozyilkan O; Yalçintaş U; Başkan S
Korean J Intern Med; 1999 Jul; 14(2):15-9. PubMed ID: 10461420
[TBL] [Abstract][Full Text] [Related]
18. Management and prevention of diabetic foot ulcers and infections: a health economic review.
Chow I; Lemos EV; Einarson TR
Pharmacoeconomics; 2008; 26(12):1019-35. PubMed ID: 19014203
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of multidrug-resistant
Sun L; Wang X; Li Z
Br J Neurosurg; 2018 Dec; 32(6):642-645. PubMed ID: 28431478
[No Abstract] [Full Text] [Related]
20. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.
Smolyakov R; Borer A; Riesenberg K; Schlaeffer F; Alkan M; Porath A; Rimar D; Almog Y; Gilad J
J Hosp Infect; 2003 May; 54(1):32-8. PubMed ID: 12767844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
